Published in Curr Med Chem Anticancer Agents on March 01, 2003
Cell-cycle synchronization reverses Taxol resistance of human ovarian cancer cell lines. Cancer Cell Int (2013) 0.87
Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs (2009) 0.84
Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. BJU Int (2011) 0.79
Anti-breast Cancer Agents Derived from Plants. Nat Prod Bioprospect (2014) 0.75
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein. Bioorg Med Chem Lett (2005) 2.80
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res (2005) 2.21
Postoperative pain after conventional laparoscopy and laparoendoscopic single site surgery (LESS) for benign adnexal disease: a randomized trial. Fertil Steril (2011) 2.04
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer (2010) 2.03
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem (2005) 1.77
4-Alkyl- and 4-phenylcoumarins from Mesua ferrea as promising multidrug resistant antibacterials. Phytochemistry (2004) 1.74
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol (2011) 1.71
Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res (2006) 1.67
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol (2006) 1.61
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood (2002) 1.57
Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc (2008) 1.56
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol (2005) 1.52
Risk of postoperative pelvic abscess in major gynecologic oncology surgery: one-year single-institution experience. Ann Surg Oncol (2010) 1.50
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer (2013) 1.48
A prospective study of laparoscopy versus minilaparotomy in the treatment of uterine myomas. J Minim Invasive Gynecol (2005) 1.48
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
Minilaparotomy in early stage endometrial cancer: an alternative to standard and laparoscopic treatment. Gynecol Oncol (2002) 1.45
Laparoendoscopic single-site surgery (LESS) for ovarian cyst enucleation: report of first 3 cases. Fertil Steril (2009) 1.44
Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. Am J Physiol Heart Circ Physiol (2008) 1.42
Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online (2001) 1.40
Incidence and risk factors for clinical failure of uterine leiomyoma embolization. Obstet Gynecol (2012) 1.39
Some criticism about postoperative pain after adnexal surgery performed by single-port versus standard laparoscopy. Fertil Steril (2012) 1.39
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res (2003) 1.32
Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J Med Chem (2006) 1.30
Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology (2004) 1.30
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene (2007) 1.29
Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol (2004) 1.29
Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. J Med Chem (2010) 1.29
Targeting CD133 antigen in cancer. Expert Opin Ther Targets (2009) 1.26
Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med (2002) 1.25
Syphilis Infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol (2012) 1.25
Use of the tubulin bound paclitaxel conformation for structure-based rational drug design. Chem Biol (2005) 1.24
CD133 antigen expression in ovarian cancer. BMC Cancer (2009) 1.23
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology (2007) 1.22
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res (2005) 1.20
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol (2003) 1.20
Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci (2002) 1.20
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol (2006) 1.19
Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem (2010) 1.19
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease. Gynecol Oncol (2002) 1.19
MiR-200c and HuR in ovarian cancer. BMC Cancer (2013) 1.18
FtsZ: a novel target for tuberculosis drug discovery. Curr Top Med Chem (2007) 1.18
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther (2003) 1.18
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res (2009) 1.17
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol (2012) 1.15
Laparoendoscopic single-site surgery for the treatment of benign adnexal disease: a prospective trial. Diagn Ther Endosc (2010) 1.14
Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Med Chem (2010) 1.14
Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry (2008) 1.13
Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res (2009) 1.13
Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study. Med Care (2012) 1.12
Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol (2008) 1.12
Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett (2005) 1.12
Molecular mechanisms of patupilone resistance. Cancer Res (2008) 1.11
Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma. Rapid Commun Mass Spectrom (2005) 1.10
Pseudo-Meigs' syndrome associated with malignant struma ovarii: a case report. Gynecol Oncol (2004) 1.10
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc (2014) 1.10
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res (2002) 1.09
The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med (2003) 1.09
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Cancer prevention in Europe: the Mediterranean diet as a protective choice. Eur J Cancer Prev (2013) 1.08
Non-surgical management of uterine fibroids. Hum Reprod Update (2008) 1.08
A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther (2005) 1.07
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One (2012) 1.07
Stereotactic radiotherapy in recurrent gynecological cancer: a case series. Oncol Rep (2009) 1.06
HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res (2010) 1.04
Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc (2007) 1.04
Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol (2005) 1.04
Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery. Tuberculosis (Edinb) (2008) 1.04
Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol (2009) 1.04
Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res (2012) 1.04
Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab (2004) 1.04
Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology (2005) 1.03
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol (2004) 1.03
Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother (2009) 1.02